Oncology Care: Trends & Future Outlook
- Ongoing research continues to reshape oncology and drug development, refining the understanding of cancer and its treatment. Experts at the 2025 ASCO Annual Meeting highlighted recent drug approvals...
- In 2024, the Food and Drug management (FDA) approved 15 new cancer drugs and 39 expanded indications for existing treatments, marking significant advancements.
- Tarlatamab, a bispecific T-cell engager, targets DLL3-expressing small cell lung cancer (SCLC) cells.
Discover groundbreaking advancements in oncology! The latest research highlights innovative therapies transforming cancer treatment, with tarlatamab showing promise for small cell lung cancer and vorasidenib offering new hope for IDH-mutated gliomas. The FDA has approved 15 new cancer drugs and expanded the indications of 39 existing treatments, signifying a pivotal shift in patient care.Learn how tarlatamab, a bispecific T-cell engager, is creating new possibilities for those facing small cell lung cancer, as well as the implications behind vorasidenib, the first targeted therapy for IDH mutations, and it’s impact on patient outcomes. Supportive care takes center stage, emphasizing the importance of managing treatment side effects. Explore the changing landscape of cancer care, understanding the crucial role of these breakthroughs. News Directory 3 delivers the latest updates from ASCO, providing key insights for patients and professionals. Discover what’s next in oncology.
New Therapies Emerge for Lung Cancer, Glioblastoma
Ongoing research continues to reshape oncology and drug development, refining the understanding of cancer and its treatment. Experts at the 2025 ASCO Annual Meeting highlighted recent drug approvals and shared insights on integrating novel cancer treatments into practice.
In 2024, the Food and Drug management (FDA) approved 15 new cancer drugs and 39 expanded indications for existing treatments, marking significant advancements. These include drugs like tarlatamab, epcoritamab, datopotamab deruxtecan, and vorasidenib, which have improved outcomes for patients with breast, lung, and brain cancers, demonstrating both efficacy and manageable safety profiles.
Tarlatamab for Small Cell Lung Cancer
Tarlatamab, a bispecific T-cell engager, targets DLL3-expressing small cell lung cancer (SCLC) cells. It activates T-cells without needing antigen presentation, often limited in SCLC.
The FDA’s accelerated approval of tarlatamab was based on data from the DeLLphi-301 trial, which showed a 40% response rate and a progression-free survival (PFS) of about 4.3 months. Survival outcomes were also promising,exceeding 20 months in some cases.
Luis G. Paz-Ares, MD, PhD, from the Hospital universitario 12 de Octubre in Madrid, Spain, noted that this BiTE drug includes an inactive component to extend its half-life.
Vorasidenib for Glioblastoma
Vorasidenib, an oral dual inhibitor of mutant IDH1 and IDH2 enzymes, can penetrate the brain.It’s the first FDA-approved targeted therapy for IDH mutations, present in about 20% of adult-type diffuse gliomas. This drug may allow for a “watchful waiting” approach instead of immediate radiation or chemotherapy.
Approval was based on the INDIGO trial (NCT04164901), which demonstrated that vorasidenib prolonged PFS and time to next intervention (TTNI), reduced tumor volume, and preserved neurocognitive function.
The trial showed a median PFS of 27.7 months for vorasidenib compared to 11.1 months for placebo. Time to next intervention also favored vorasidenib. Patients on vorasidenib experienced a gradual reduction in tumor volume, averaging a 2.5% decrease every six months.
What’s next
As cancer research advances,next-generation therapies are transforming standards of care. Oncologists and oncology pharmacists are focused on optimizing outcomes and maintaining quality of life as thay integrate these new agents into practice.